3rd Manufacturing Processes for Medical Technology Exhibition and Conference sets the stage as the industry’s knowledge-information exchange platform
Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
Dividella AG, a Medipak Systems company, welcomed guests to the two-day pharma event in its new premises in Grabs, Switzerland.
Quotient Clinical, the Translational Pharmaceutics company, is holding a series of formulation development and drug delivery seminars this June and July.
Teva Pharmaceutical Industries, Ltd. announced that it will voluntarily suspend sales, marketing and distribution of ZECUITY® (sumatriptan iontophoretic transdermal system).
FDA Accepted Charleston Laboratories, Inc. and Daiichi Sankyo’s New Drug Application (NDA) for CL-108
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for CL-108 for the relief of moderate to severe pain while preventing or reducing the associated opioid-induced nausea and vomiting (OINV).
Ziarco Pharma Ltd a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, today announces positive, full results from its first Phase 2a proof of concept study with ZPL-389 in adults.
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
ViiV Healthcare announced that the US FDA has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets, reducing the weight limit from at least 40kg to at least 30kg, in ages 6 to less than 12 years old, for the treatment of HIV-1 in children and adolescents.
Agreement expands commercial reach for anaesthetics and supports the Company’s sharp focus on innovative new medicines in its three main therapy areas.
Janssen Phase 3 Data Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improved Signs
Janssen Research & Development, LLC announced results from a pivotal Phase 3 study evaluating subcutaneous sirukumab (CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
Pfizer Inc. announced that the U.S. FDA Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, “management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.”
Page 1 of 91